infliximab

Last reviewed 01/2018

Infliximab is a chimeric humanised mouse anti-TNF monoclonal antibody, that binds to and inhibits human TNF-alpha.

It has been used in the treatment for acute Crohn's disease, but was primarily designed for the treatment of rheumatoid arthritis.

It is given by intravenous infusion at 0,2 and 6 weeks then every 8 weeks thereafter. It is licensed for concomitant use with Methotrexate in adults with RA responding inadequately to DMARDs including methotrexate.

Check the Summary of Product Characteristics before prescribing this drug.